AI biology company Prima Mente unveiled Pleiades, an AI model that analyses DNA methylation patterns in cell‑free DNA to detect early‑stage Alzheimer’s and Parkinson’s from blood. The company reported an 89% detection rate in real‑world cohorts that rose to 97% when combined with neurodegenerative protein biomarkers such as pTau‑217. Pleiades is being trained on NVIDIA DGX Cloud infrastructure via a partnership with Nebius and is deployed in a live SANDBOX clinical study across 15 UK sites to aid patient classification and NHS waitlist management. Prima Mente plans to use the model for diagnostic stratification and has longer‑term ambitions to develop therapeutics. If validated in larger, independent cohorts, Pleiades could offer a minimally invasive alternative to CSF sampling and imaging for early neurodegeneration detection, with implications for screening, trial enrollment, and targeted interventions.